Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Plasma levels of soluble CD30 are increased in children with chronic renalfailure and with primary growth deficiency and decrease during treatment with recombination human growth hormone
Autore:
Barbano, G; Cappa, F; Prigione, I; Pistoia, V; Cohen, A; Chiesa, S; Gusmano, R; Perfumo, F;
Indirizzi:
Ist Giannina Gaslini, Childrens Hosp, Dept Pediat Nephrol, I-16148 Genoa, Italy Ist Giannina Gaslini Genoa Italy I-16148 t Nephrol, I-16148 Genoa, Italy Ist Giannina Gaslini, Childrens Hosp, Oncol Lab, I-16148 Genoa, Italy Ist Giannina Gaslini Genoa Italy I-16148 Oncol Lab, I-16148 Genoa, Italy Ist Giannina Gaslini, Childrens Hosp, Dept Pediat, I-16148 Genoa, Italy Ist Giannina Gaslini Genoa Italy I-16148 pt Pediat, I-16148 Genoa, Italy
Titolo Testata:
NEPHROLOGY DIALYSIS TRANSPLANTATION
fascicolo: 9, volume: 16, anno: 2001,
pagine: 1807 - 1813
SICI:
0931-0509(200109)16:9<1807:PLOSCA>2.0.ZU;2-H
Fonte:
ISI
Lingua:
ENG
Soggetto:
FACTOR-I; HODGKINS-DISEASE; IMMUNE FUNCTION; T-CELLS; RESPONSES; THERAPY; SUBSET; ADULTS;
Keywords:
CD30; chronic renal failure; growth hormone therapy; primary growth hormone deficiency; T helper 2 (Th2) lymphocytes;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
23
Recensione:
Indirizzi per estratti:
Indirizzo: Barbano, G Ist Giannina Gaslini, Dept Nephrol, Largo G Gaslini 5, I-16148 Genoa, Italy Ist Giannina Gaslini Largo G Gaslini 5 Genoa Italy I-16148 aly
Citazione:
G. Barbano et al., "Plasma levels of soluble CD30 are increased in children with chronic renalfailure and with primary growth deficiency and decrease during treatment with recombination human growth hormone", NEPH DIAL T, 16(9), 2001, pp. 1807-1813

Abstract

Background. Previous studies have suggested that in vivo Th2 lymphocyte activation is related to increased soluble CD30 (sCD30) plasma levels. As various hormones (dehydroepiandrosterone, glucocorticoids, progesterone) can regulate the Th1/Th2 balance, and because growth hormone (GH) enhances lymphocyte function, we measured sCD30 plasma levels, before and after treatmentwith recombinant human GH (rhGH), in children with growth failure due to chronic renal failure (CRF) or to isolated GH deficiency in order to evaluate the potential effects of rhGH treatment on Th1/Th2 balance. Methods. sCD30 plasma levels were determined by ELISA assay in 30 childrenwith CRF (mean age 10.7 +/- 3.7 years), in five children with isolated GH deficiency (mean age 11.4 +/- 2.6 years), and in 10 normal controls (mean age 10.1 +/- 3.5 years). Results. sCD30 levels were higher in the 30 children with CRF than in the 10 controls (179.8 +/- 79.4 vs 11.3 +/- 10.9 U/ml, P < 0.001) exhibiting aninverse correlation with glomerular filtration rate (GFR) (r=-0.7860, P < 0.001). In 11 children with CRF, after 19.9 +/- 16.7 months of rhGH treatment, a decrease of sCD30 plasma level (170 +/- 50 vs 134 +/- 49 U/ml, P < 0.01) was observed. The five children with primary GH deficiency had higher sCD30 plasma level than controls (mean 147 +/- 105 vs 11 +/- 10U/ml, P < 0.004) and sCD30 plasma levels decreased to 95.2 +/- 109.6 U/ml after rhGH treatment. Conclusions. The finding that rhGH treatment decreased sCD30 plasma levelsin children with CRF, and that children with primary GH deficiency had higher sCD30 plasma levels than controls, suggest that GH may regulate CD30 expression and possibly the balance of Th1/Th2. Whether the uraemia-induced increase in sCD30 is due to decreased renal excretion, to overproduction or both, remains to be determined.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 03/04/20 alle ore 13:15:12